ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

ExeVir Bio, a technology platform with potential to generate robust antiviral therapies.

ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family offices. ...

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.

Register

Login

Subscribe